bluuebunny/crossref_metadata_2025_split huggingface dataset:
Prompt engraftment using autologous peripheral blood stem cells for double autologous bone marrow rescue
Authors: Hillyer Christopher D. , Comenzo Raymond L. , Miller Kenneth B. , Schenkein David P. , Tiegerman Karen O. , Fogaren Terry A. , Wazer David E. , Parker Leroy , Abrams Ross A. , Desforges Jane F. , Rudders Richard A. , Berkman Eugene M. 
Published: February 2007

AbstractA patient with Hodgkin's Disease, stage IIIA, was treated for recurrent disease with autologous peripheral blood stem cells after ablative chemotherapy. Bone marrow rescue occurred promptly and his disease was significantly reduced. Ablative chemotherapy was administered again and a second bone marrow rescue with peripheral blood stem cells was successful. Sequential peripheral blood stem cell bone marrow rescue, following high dose chemotherapy, may provide an alternative approach in selected patients.
Helper‐suppressor T‐cell leukemia: Unusual phenotype controlled with low‐dose deoxycoformycin
Authors: Adler Mark J. , Hershberg Robert , Yu Alice 
Published: February 2007

AbstractPresented is an unusual case of chronic T‐cell leukemia. Immunophenotypic profile revealed the leukemia cells to express T4 and T8 surface markers simultaneously. The patient was treated with low‐dose deoxycoformycin and control of symptoms and lymphocyte levels shown to correlate with ADA and dATP/ATP levels.
GM‐CSF‐mediated impairment of liver to synthesize albumin, cholinesterase, and cholesterol
Authors: Takahashi Masuhiro , Nikkuni Kohji , Moriyama Yoshiaki , Shibata Akira 
Published: February 2007

AbstractSerum albumin, cholinesterase, and cholesterol were measured in ten patients with aplastic anemia and eight with myelodysplastic syndrome who received the administration of recombinant human GM‐CSF. Serum albumin, cholinesterase, and cholesterol were significantly lowered by the administration of GM‐CSF and recovered after the cessation of GM‐CSF. These data suggest that GM‐CSF impairs the biosynthesis of liver cells and that cholesterol‐lowering activity of GM‐CSF, which is previously reported, is due to the impairment of liver biosynthesis by GM‐CSF.
Platelet satellitosis to polymorphonuclears: Cytochemical, immunological, and ultrastructural characterization of eight cases
Authors: Bizzaro Nicola 
Published: February 2007

AbstractSatellitosis of platelets to polymorphonuclears was observed in eight patients. This phenomenon occurred only in blood anticoagulated by EDTA at room temperature. In vivo and in vitro platelet and neutrophil function were normal. Electron microscopy studies showed normal structures in both cells but demonstrated platelet phagocytosis by neutrophils. In all cases we were able to transfer the platelet satellitosis factor by mixing platelet plasma (or serum) with whole blood from ABO compatible healthy controls; conversely, when the same plasma (or serum) was pre‐incubated with anti‐IgG serum, satellitosis to normal blood was not observed. While this finding suggests that a plasmatic protein with the properties of an IgG immunoglobulin was probably responsible for the phenomenon, we were unable to correlate it with the clinical condition of the patient, functional abnormalities of the blood components, or drugs.
Absent neutrophil alkaline phosphatase in the eosinophilia myalgia syndrome associated with L‐tryptophan use
Authors: Jaffe Jeffrry P. , Gertner Elie , Miller Wesley 
Published: February 2007

AbstractThe clinical constellation of leukocytosis, thrombocytosis, and low or absent stainable neutrophil alkaline phosphatase (NAP) is considered characteristic of chronic myelogenous leukemia (CML) [1]. CML with eosinophilic differentiation (eosinophilic leukemia) is well described [2], and leukemia and other clonal hematologic malignancies are associated with the syndrome of eosinophilic fasciitis [3]. We describe leukocytosis, thrombocytosis, eosinophilia, mild basophilia, and absent stainable NAP, initially suggesting the diagnosis of CML in a patient with the eosinophilia myalgia syndrome associated with L‐tryptophan use, a condition resembling eosinophilic fasciitis. Cytogenetic and molecular genetic studies failed to demonstrate a clonal proliferation of eosinophils.
Treatment with granulocyte‐macrophage colony stimulating factor and the adult respiratory distress syndrome
Authors: Verhoef Gregor , Boogaerts Marc 
Published: February 2007

AbstractWe report a case of a patient who developed a fatal adult respiratory distress syndrome (ARDS) during treatment with rh granulocyte‐macrophage colony stimulating factor (rhGM‐CSF) (250 mcg/m2/day s.c.) and low‐dose cytosine‐arabinoside (Ara‐C) (20 mg/m2/day s.c.). Several mechanisms which might explain the lung tissue damage in this patient were explored. GM‐CSF increased the expression of the glycoproteins CD11B and CD18 on the surface of his neutrophils, which may have increased the adhesiveness of neutrophils to the pulmonary endothelium. In addition, GM‐CSF primed the neutrophils of the patient to an enhanced release of superoxide anions. Both findings may at least partially explain why GM‐CSF exerted a deleterious action on the pulmonary endothelial integrity in this patient. Other factors, such as increased platelet‐activating factor production by the neutrophils or tumor necrosis factor‐mediated mechanisms, may also have played a role. ARDS as a complication of low‐dose Ara‐C seems less plausible.
Acute lymphoblastic leukemia with azurophilic granules that contain ultrastructural myeloperoxidase activity
Authors: Tauchi Tetsuzo , Ohyashiki Kazuma , Ohyashiki Junko H. , Saito Midori , Nakazawa Shinpei , Enomoto Yasuhiro , Hosoda Yasuhiro , Toyama Keisuke 
Published: February 2007

AbstractWe present a case of acute lymphoblastic leukemia (ALL) in which the leukemic cells had cytoplasmic azurophilic granules. Surface marker studies revealed that the leukemic cells expressed CD10 (CALLA), CD19, CD20, and HLA‐DR antigens. Cytochemical studies by light microscopy revealed that the blasts were negative for myeloperoxidase, PAS staining, and double esterase staining, supporting the diagnosis of ALL. However, an ultrastructural study demonstrated that some of the cytoplasmic granules were myeloperoxidase (MPO) positive. Our findings suggested that leukemic transformation in this case may have taken place at a stage ontogenetically close to the pluripotent stem cell. Furthermore, the present case indicates the existence of a new form of ALL is characterized by MPO‐positive granules detectable by ultracytochemistry and lymphoid‐associated surface markers.
Transitions in CD45 isoform expression indicate continuous differentiation of a monoclonal CD5+ CD11b+ B lineage in Waldenstrom's macroglobulinemia
Authors: Jensen Gitte S. , Andrews E. Joy , Mant Michael J. , Vergidis Rucy , Ledbetter Jeffrey A. , Pilarski Linda M. 
Published: February 2007

AbstractWaldenstrom's macroglobulinemia (WM) has been hypothesized to be a pleomorphic B‐cell malignancy with persistent maturation towards plasma cells in all lymphoid tissue. This proposal is based on detection of a heterogeneous density of monoclonal Ig on peripheral blood B‐cells in patients with WM. We now present data derived from 2‐ and 3‐color immunofluorescence and flow cytometric analysis that strongly supports this hypothesis. Abnormally high numbers of B lineage cells, defined by expression of CD19, CD20, and CD24, were found among peripheral blood mononuclear cells (PBMC). These B‐cells are monoclonal as defined by light chain expression and by the existence of rearranged Ig genes (Southern blot analysis), although they exhibit heterogeneity in the density of surface light chain. Unlike normal PBMC B‐cells, the monoclonal B‐cells bear CD5 and CD10 (CALLA), express adhesion and adhesion‐related molecules (CD11b, CD9), and appear to be actively differentiating during the course of the disease, based on the pattern of CD45 isoform expression. At any given point in time, the population of monoclonal B‐cells is heterogeneous in differentiation stage based on transitions in the expression of CD45 isoforms from expression of CD45RA, the high molecular mass isoforms of CD45, to the low molecular mass isoform CD45R0 which appears only on very late stage B‐cells and early plasma cells. For one patient, analysis of CD45 isoform expression over 2 years showed that the monoclonal B‐cell population as a whole progressed towards terminal differentiation as defined by loss of CD45RA and acquisition of CD45R0. This indicates a continuously differentiating lineage of an unusual B‐cell phenotype, and/or malignant transformation of a distinct lineage of B‐cells in WM.
Concise review: Genetic bases for sideroblastic anemia
Authors: Nusbaum Neil J. 
Published: February 2007

AbstractThe best‐documented mode of transmission of familial sideroblastic anemia is as an X‐linked trait. Mitochondrial mutation has also occasionally been noted in association with sideroblastic anemia, but it is likely to be present more often than has so far been described. It should especially be suspected in cases of inherited multisystem disease, where the pedigrees do not indicate a sex predominance among those affected, and where there is no evidence of transmission by the paternal line. Sporadic cases of sideroblastic anemia may represent mitochondrial mutations either at the germ cell or the somatic cell, and the most sensitive strategy of screening for both would be the study of mitochondrial DNA from circulating erythrocytes. It seems likely that such studies would extend the understanding of mitochondrial function and disease.
Myelodysplastic transformation of polycythemia vera: Case report and review of the literature
Authors: Shamdas Glenn J. , Spier Catherine M. , List Alan F. 
Published: February 2007

AbstractWe report a case of refractory anemia with excess blasts (RAEB) developing in a 67‐year old man with a history of polycythemia vera; results of cytogenetic and immunophenotyping studies are described. In this report the clinical, cytogenetic and hematologic features of myelodysplasia complicating polycythemia vera are reviewed. Results of immunophenotyping and cytogenetic studies, and the preponderance of cases developing after myelosuppressive therapy suggest that in the majority of cases myelodysplasia is treatment‐related.
Simultaneous occurrence of factor VIIIC inhibitor and antinuclear antibody in postpartum period
Authors: Marwaha Neelam , Sarode Ravindra , Chauhan A. P. , Joseph  , Varma S. , Dash S. 
Published: February 2007

AbstractWe are describing a rare case of acquired factor VIIIC inhibitor in postpartum period who also had strongly positive antinuclear antibody. On immunosuppression with prednisolone and azathioprine, both antibodies disappeared after 4 months of therapy.
Recombinant human erythropoietin for a Jehovah's witness with anemia of thermal injury
Authors: Boshkov Lynn K. , Tredget Edward E. , Janowska‐Wieczorek Anna 
Published: February 2007

AbstractWe report the use of recombinant human erythropoietin (rh‐Ep) as an alternative to transfusion therapy in a burn victim who was a Jehovah's Witness and refused blood transfusion. Despite endogenous elevated erythropoietin levels, the patient was reticulocytopenic and administration of rh‐Ep was accompanied by a 10‐fold increase in reticulocyte response and a rise in hemoglobin from 7.4 to 10.4 g/dl over a 12‐day period. We suggest that the exogenously administered erythropoietin overcame a clinically inadequate endogenous erythropoietin response.
Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin‐2
Authors: Lotzová Eva , Savary C. A. , Schachner J. R. , Huh J. O. , McCredie K. 
Published: February 2007

AbstractWe have studied the cytotoxic profile and distribution of lymphocyte subsets of patients with acute myelogenous leukemia in second remission, after continuous infusion with recombinant interleukin‐2 (IL‐2). The patients received repetitive cycles of 1–1.25 × 106 U/m2/day of IL‐2, given as 4 days continuous intravenous infusion followed by a 3‐day treatment‐free interval for the first 4 weeks. Patients receiving >4 cycles were treated with the same dose of IL‐2 continuously for 4 days, followed by a 10‐day treatment‐free interval. These studies showed that IL‐2 treatment resulted in the generation of peripheral blood cytotoxic activity against both NK‐susceptible, K‐562, and NK‐resistant Daudi cell lines. In most patients, enhancement of lytic activity increased with the number of IL‐2 infusions. The cytotoxicity in some patients increased as much as 700‐fold and 830‐fold against K‐562 and Daudi cells, respectively. It is of importance that oncolytic activity was also induced in bone marrow compartment (up to 182‐fold against K‐562). Some decline in cytotoxicity was observed within 14 days after initiation of IL‐2 infusion in peripheral blood, but high levels of lytic activity persisted at this time in bone marrow. It is of interest to note that the cytotoxicity of in vivo IL‐2 primed lymphocytes was further potentiated by IL‐2 in vitro. Importantly, the cytotoxic cells induced in vitro displayed lytic activity against fresh leukemic blasts. Phenotypic analysis demonstrated that CD3−, CD56+ NK cells were significantly increased by in vivo IL‐2 treatment (34 to 47‐fold in absolute numbers), while CD3+, CD56+ T‐cell subset remained low. Characterization of cytotoxic cells using the complement‐dependent assay and monoclonal antibodies indicated that both the in vivo‐induced and ex vivo‐potentiated lytic function was mediated by CD3−, CD56+, CD16+/– NK cells.
Lymphomas following cardiac transplantation. Case report and review of the literature
Authors: Sklarin Nancy T. , Dutcher Janice P. , Wiernik Peter H. 
Published: February 2007

AbstractThe success of allogeneic organ transplantation is in great part due to pharmacologic advances in the area of immunosuppressive therapy. However, this achievement has been attained at the price of an unexpectedly high incidence of malignancies in this transplant population. Lymphoid malignancies predominate in this and other immunodeficiency states. There is some controversy in the literature over the clonal or malignant nature of these proliferations. This paper presents a case of Burkitt‐like lymphoma occurring after cardiac transplantation. The role of Epstein–Barr virus in the pathogenesis of this disorder is reviewed as are multidisciplinary approaches to its management.
Amegakaryocytic thrombocytopenia of 4 years duration: Successful treatment with antithymocyte globulin
Authors: Trimble Malcolm S. , Brain Michael C. , Glynn Michael F. X. 
Published: February 2007

AbstractAcquired amegakaryocytic thrombocytopenic purpura (AATP) is a rare cause of thrombocytopenia. Since it is a syndrome of diverse etiologies, the optimal treatment is often uncertain. In a patient with longstanding AATP, a complete remission was obtained with antithymocyte globulin.
Refractory ascites in the chronic myeloproliferative syndrome: A case report
Authors: Jacobs Peter , Wood Lucille , Robson Simon 
Published: February 2007

AbstractIn a patient with myelofibrosis, tense ascites refractory to conventional therapy resulted from extensive seeding of the peritoneum with colonies of extramedullary haematopoiesis. Whole abdominal radiation was found to be effective and well tolerated, and brought about prompt and lasting resorption of the exudate, with weight reduction and improvement in performance status from 50% to 90% on the Karnofsky rating.
Light chain composition of serum granulocyte binding immunoglobulins
Authors: Shastri Kaushik A. , O'Connor Brian M. , Logue Gerald L. , Shimm David S. , Rustagi Pradip K. 
Published: February 2007

AbstractSerum granulocyte binding IgG, IgM, and the light chain composition of granulocyte binding immunoglobulins were measured in 58 adult subjects, including 8 normal individuals, 6 with Felty syndrome, 6 with chronic idiopathic neutropenia, 32 with B‐cell chronic lymphocytic leukemia (CLL), and 6 with multiple myeloma. An abnormal kappa/lambda ratio of granulocyte binding immunoglobulins was detected in 12 of 32 patients with CLL. Neutropenia in patients with CLL did not correlate with an abnormal kappa/lambda ratio or excess granulocyte binding IgG, but did correlate with granulocyte binding IgM (P < 0.02). Eight of the 12 patients (5 with chronic idiopathic neutropenia and 3 with Felty syndrome) with an immune neutropenia without underlying neoplastic disorder had light chain restricted granulocyte binding immunoglobulins. Of all patients' sera with light chain restriction, 76% were of lambda light chain isotype. Thus, the frequent detection of light chain restriction of granulocyte binding immunoglobulins is not a reflection of malignancy but is suggestive of the somatic mutation of immunoglo‐bulin light chain genes.
Establishment of a new Epstein‐Barr virus nuclear antigen‐positive B‐cell line, BALL‐2, with t(8;14)(q24;q32) chromosome abnormality from B‐cell acute lymphoblastic leukemia, L2
Authors: Kubonishi Ichiro , Daibata Masanori , Yano Shoki , Isobe Masaharu , Kurosawa Nobuyuki , Nagumo Hideki , Ogita Zen‐Ichi , Ohyashiki Junko H. , Toyama Keisuke , Miyoshi Isao 
Published: February 2007

AbstractA new Epstein‐Barr virus nuclear antigen (EBNA)‐positive B‐cell line, designated BALL‐2, was spontaneously established from the peripheral blood of a 14‐year‐old boy with an EBNA‐negative B‐cell acute lymphoblastic leukemia (B‐ALL), L2 in the French‐American‐British classification. The BALL‐2 cell line grew in suspension with or without forming clumps of cells. The cultured cells exhibited lymphoid morphology with indented or tabulated nuclei, prominent nucleoli, and relatively abundant cytoplasm. Immunologic and cytogenetic studies showed that the BALL‐2 cell line expressed the B‐cell phenotype, Cplg+, Smlg+, CD19+, CD20+, CD38+, la+, and had chromosome translocation, t(8;14)(q24;q32). The same phenotypic and chromosome markers were present in original leukemia cells. These results indicated that the cell line was derived from the patient's leukemia cells. Unexpectedly, however, BALL‐2 cells were positive for EBNA and EB virus DMA. Gene analysis of the BALL‐2 cell line showed biallelic rearrangements in the JH locus. One of the JH rearrangement comigrated with a rearranged c‐myc gene, indicating the translocation had occurred between JH and c‐myc loci. The t(8;14) abnormality is a known chromosome marker of Burkitt lymphoma and L3 type ALL. Our studies revealed that this translocation and myc gene rearrangement can also be found in L2 type B‐ALL.
Spinal cord compression secondary to extramedullary hematopoiesis: A noninvasive management based on MRI
Authors: Hassoun Hani , Lawn‐Tsao Lilly , Langevin Eugene R. , Lathi Ellen S. , Palek Jiri 
Published: February 2007

AbstractWe report the first case of spinal cord compression secondary to extramedullary hematopoiesis in which the diagnosis was made by magnetic resonance imaging (MRI). Based on the great advantage of this imaging test that visualizes the entire spine, the noninvasive approach to such patients, using low‐dose radiation therapy and guided by MRI is discussed. This management appears to be both efficacious and safe.
Expression of transferrin receptors on monocytes in hemochromatosis
Authors: Adams Paul C. , Chau Luan A. , White Martin , Lazarovits Andrew 
Published: February 2007

AbstractTo assess whether an abnormality in transferrin receptor expression or regulation could represent an underlying metabolic defect in the reticuloendothelial (RE) system in hemochromatosis, monocytes were analyzed for the expression of the transferrin receptor using a monoclonal antibody (Act II) to the transferrin receptor (CD71) and flow cytometric analysis. Hemochromatosis patients (n = 14), and normal volunteers with no clinical evidence of iron overload (n = 14) were studied. A significant inverse relationship was observed for the relationship between the expression of transferrin receptor on monocytes and log(hepatic iron concentration) in hemochromatosis patients (r = −0.59, P < 02) and also for the relationship between the expression of transferrin receptor and log(serum ferritin) in normal volunteers (r = −0.90, P <.001). There was no significant difference in the mean expression of monocyte transferrin receptor between hemochromatosis patients and normal volunteers. However, the expression of the transferrin receptor in hemochromatosis patients was disproportionately higher than would be predicted from the relationship between serum ferritin and transferrin receptor expression in normal volunteers. The inverse relationship of the monocyte transferrin receptor relative to body iron stores in hemochromatosis is consistent with observations in other tissues, and suggests that non‐transferrin iron metabolism, including ferritin, requires further investigation in the RE cell in hemochromatosis.
Intravenous gamma globulin decreases platelet‐associated IgG and improves transfusion responses in platelet refractory states
Authors: Zeigler Zella R. , Shadduck Richard K. , Rosenfeld Craig S. , Winkelstein Alan , Przepiorka Donna , Kiss Joseph E. , Duquesnoy Rene J. , Marrari Marilyn 
Published: February 2007

AbstractIn an attempt to improve platelet transfusion responses, intravenous immunoglobulin (IV‐IgG) was administered to 19 patients who were refractory to random and best available HLA‐matched platelets. A response to IV‐IgG was defined as two or more successive transfusions of HLA‐matched products that provided recoveries greater than 30%. Thirteen of 19 (68%) patients responded to therapy at a median time of 7 days after initiation of IV‐IgG (range = 2–17). Baseline platelet associated IgG levels (PaIgG) were elevated in both the responders (61.6 ± 76.2) (mean ± SD) and the non‐responders (47.0 ± 46.3 fg/plt). Post‐therapy, PaIgG levels remained unchanged in the nonresponders but were decreased significantly (p = 0.05) to 11.1 ± 6.2 fg/plt in the responders. The latter levels were similar to those (11.6 ± 8.2 fg/plt) measured in a series of 36 transfusion responsive patients. This apparent decline in PaIgG was not explained by differences in lymphocytotoxic antibodies (LCT‐Ab) after therapy. Moreover, a high degree of alloimmunization was associated with a poorer response to IgG. Only two of eight patients with LCT panel‐reactive antibody (PRA) of > 85% were responders. By contrast, improved transfusion outcomes were seen uniformly in patients with PRA ≦ 85%. Improved recoveries were obtained using LCT‐Ab compatible but not incompatible platelets. The median increment (% predicted) with compatible platelets before therapy was 6.0 ± 9.9 (SD). Post‐IgG, median recoveries were 37.0 ± 31.2 percent, P < 0.001. These findings suggest that IV‐IgG may alter destructive mechanisms that affect the survival of compatible platelets in refractory patients.